-
1.
公开(公告)号:US11986531B2
公开(公告)日:2024-05-21
申请号:US17387621
申请日:2021-07-28
发明人: Andrew P. Crew , Keith R. Hornberger , Jing Wang , Saul Jaime-Figueroa , Hanqing Dong , Kurt Zimmermann , Craig M. Crews
IPC分类号: C07D401/14 , A61K31/437 , A61K47/55 , A61P35/00 , C07D413/14 , C07D417/14 , C07D471/04 , C07D519/00
CPC分类号: A61K47/55 , C07D413/14 , C07D417/14 , C07D471/04 , C07D519/00
摘要: The present disclosure relates to bifunctional compounds, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A-RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.
-
公开(公告)号:US11512083B2
公开(公告)日:2022-11-29
申请号:US16905641
申请日:2020-06-18
发明人: Andrew P. Crew , Craig M. Crews , Xin Chen , Hanqing Dong , Caterina Ferraro , Yimin Qian , Kam Siu , Jing Wang , Meizhong Jin , Michael Berlin , Kurt Zimmermann
IPC分类号: C07D521/00 , C07D413/14 , C07D471/12 , C07D417/14 , C07D207/16 , C07D207/26 , C07D401/06 , C07D401/10 , C07D403/06 , C07D405/06 , C07D405/12 , C07D413/06 , C07D413/12 , A61K31/422 , A61K31/437 , A61K31/4439 , A61K31/5377 , C07D471/04 , A61K45/06 , C07D417/12 , C07D403/14 , C07D401/14 , C07D405/14 , C07D495/04
摘要: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.
-
公开(公告)号:US11384063B2
公开(公告)日:2022-07-12
申请号:US16810764
申请日:2020-03-05
发明人: Andrew P. Crew , Hanqing Dong , Jing Wang , Yimin Qian
IPC分类号: C07D401/14 , C07D471/04 , C07D409/12 , C07D403/06 , A61P35/00 , C07D405/14 , C07D413/14 , C07D417/12 , C07D417/14 , C07D403/14
摘要: The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a cereblon, Von Hippel-Lindau ligase-binding moiety, Inhibitors of Apotosis Proteins, or mouse double-minute homolog 2 ligand, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
-
公开(公告)号:US20220144809A1
公开(公告)日:2022-05-12
申请号:US17512219
申请日:2021-10-27
发明人: Hanqing Dong , Lawrence B. Snyder , Jing Wang
IPC分类号: C07D401/14 , A61K45/06
摘要: Bifunctional compounds, which find utility as modulators of androgen receptor (AR), are described herein. In particular, the bifunctional compounds of the present disclosure contain on one end a moiety that binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds AR, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aberrant regulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
-
公开(公告)号:US20220127279A1
公开(公告)日:2022-04-28
申请号:US17570197
申请日:2022-01-06
发明人: Andrew P. Crew , Craig M. Crews , Hanqing Dong , Yimin Qian , Jing Wang
IPC分类号: C07D495/14 , A61K45/06 , C07D417/12 , C07D401/14 , C07D207/16 , C07D401/12 , C07D405/14 , A61K31/506 , A61K47/55 , A61K31/436 , A61K31/337 , A61K31/4995 , A61K31/593 , A61K31/4545 , A61K31/4184 , A61K31/704 , A61K31/664
摘要: The description relates to MDM2 binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the description provides compounds, which contain on one end a ligand which binds to the MDM2 E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.
-
6.
公开(公告)号:US11191741B2
公开(公告)日:2021-12-07
申请号:US15851053
申请日:2017-12-21
发明人: Andrew P. Crew , Lawrence B. Snyder , Jing Wang , Yimin Qian , Michael Berlin
IPC分类号: A61K31/166 , A61K31/405 , A61K47/54 , A61P35/00 , A61K38/45 , C12N9/10 , A61K31/351 , C07D471/04 , C07D401/14 , C07D405/14 , C07D405/12 , C07D417/14 , C07D409/14 , A61K47/55
摘要: The present disclosure relates to bifunctional compounds, which find utility as modulators of enhancer of zeste homolog 2 (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
-
公开(公告)号:US11161841B2
公开(公告)日:2021-11-02
申请号:US16375643
申请日:2019-04-04
发明人: Andrew P. Crew , Keith R. Hornberger , Jing Wang , Hanqing Dong
IPC分类号: C07D417/14 , A61P35/00 , C07D401/14 , C07D413/14 , C07D471/04
摘要: The present disclosure relates to bifunctional compounds, which find utility as modulators of Kirsten rat sarcoma protein (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation, accumulation, and/or overactivation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
-
公开(公告)号:US20210040081A1
公开(公告)日:2021-02-11
申请号:US17082839
申请日:2020-10-28
发明人: Andrew P. Crew , Yimin Qian , Hanqing Dong , Jing Wang
IPC分类号: C07D417/14 , C07K5/062 , C07D403/12 , C07D403/14 , C07D413/14
摘要: The present disclosure relates to compounds and a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing the compounds, and processes for their preparation. The disclosure also relates to the use of the compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of the estrogen receptor, including degrading the estrogen receptor, the treatment of diseases and conditions mediated by the estrogen receptor.
-
公开(公告)号:US12053469B2
公开(公告)日:2024-08-06
申请号:US17207325
申请日:2021-03-19
发明人: Erika Araujo , Michael M. Berlin , Steven M. Sparks , Jing Wang , Wei Zhang
IPC分类号: A61K31/506 , A61K31/496 , A61K31/5377 , A61K45/06 , A61P25/16 , C07D401/14 , C07D413/14 , C07D487/10
CPC分类号: A61K31/506 , A61K31/496 , A61K31/5377 , A61K45/06 , A61P25/16 , C07D401/14 , C07D413/14 , C07D487/10
摘要: Bifunctional compounds, which find utility as modulators of leucine-rich repeat kinase 2 (LRRK2), are described herein. In particular, the hetero-bifunctional compounds of the present disclosure contain on one end a moiety that binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds LRRK2, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The hetero-bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aberrant regulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
-
公开(公告)号:US11981683B2
公开(公告)日:2024-05-14
申请号:US17699082
申请日:2022-03-19
发明人: Erika Marina Vieira Araujo , Michael Berlin , Hanqing Dong , Steven M. Sparks , Jing Wang , Wei Zhang
IPC分类号: C07D401/14 , A61K45/06 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/08 , C07D487/10 , C07D498/10
CPC分类号: C07D498/10 , A61K45/06 , C07D401/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/08 , C07D487/10
摘要: Bifunctional compounds, which find utility as modulators of leucine-rich repeat kinase 2 (LRRK2), are described herein. In particular, the hetero-bifunctional compounds of the present disclosure contain on one end a moiety that binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds LRRK2, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The hetero-bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aberrant regulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
-
-
-
-
-
-
-
-
-